Abstract
Objective
Urinary copper excretion rates and non-caeruloplasmin associated copper concentrations are increased in patients with Wilson disease. However, there is little literature describing the monitoring of these parameters over the long term.
Methods
This is a monocentric retrospective study including data collected between 2003 and 2015 from 321 patients with Wilson disease by chart review. The patients were under therapy with D-penicillamine, trientine, or zinc. 24-h urinary copper excretion rates, non-caeruloplasmin associated copper, and total serum copper concentrations were determined at the start of therapy, as well as 6, 12, 18, 24, 36, and ≥ 60 months after the start of therapy. For patients taking chelating agents, all parameters were measured while under continued therapy, as well as after a 48-h dose interruption. A mathematical formula to predict 24-h urinary copper excretion rates under different therapies was established.
Results
In all treatment groups, urinary copper excretion rates decreased over time, but the inter-individual variation of the results was high. Non-caeruloplasmin associated copper concentrations tended to decline over time, but with a higher variation of results than that observed for urinary copper excretion rates.
Conclusion
Due to their variability, urinary copper excretion rates and serum copper concentrations are less than ideal parameters by which to monitor the benefit of a copper-reducing therapy. Urinary copper excretion rates seem to be more suitable than non-caeruloplasmin associated copper concentrations for this purpose.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bandmann O, Weiss KH, Kaler SG (2015) Wilson's disease and other neurological copper disorders. Lancet Neurol 14:103-113
Brewer GJ (1995) Practical recommendations and new therapies for Wilson’s disease. Drugs 50:240–249
Das SK, Ray K (2006) Wilson’s disease: an update. Nat Clin Pract Neurol 2:482–493
European Association for Study of Liver (2012) EASL clinical practice guidelines: Wilson’s disease. J Hepatol 56:671–685
Ferenci P, Caca K, Loudianos G et al (2003) Diagnosis and phenotypic classification of Wilson disease. Liver Int 23:139–142
Gaffney D, Fell GS, O’Reilly DS (2000) ACP best practice no 163. Wilson’s disease: acute and presymptomatic laboratory diagnosis and monitoring. J Clin Pathol 53:807–812
Martins da Costa C, Baldwin D, Portmann B, Lolin Y, Mowat AP, Mieli-Vergani G (1992) Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson’s disease. Hepatology 15:609–615
Medici V, Rossaro L, Sturniolo GC (2007) Wilson disease—a practical approach to diagnosis, treatment and follow-up. Dig Liver Dis 39:601–609
Müller T, Koppikar S, Taylor RM et al (2007) Re-evaluation of the penicillamine challenge test in the diagnosis of Wilson’s disease in children. J Hepatol 47:270–276
Park RH, McCabe P, Fell GS, Russell RI (1991) Wilson’s disease in Scotland. Gut 32:1541–1545
Pfeiffer RF (2007) Wilson’s disease. Semin Neurol 27:123–132
Ritland S, Steinnes E, Skrede S (1977) Hepatic copper content, urinary copper excretion, and serum ceruloplasmin in liver disease. Scand J Gastroenterol 12:81–88
Roberts EA, Schilsky ML; American Association for Study of Liver Diseases (AASLD) (2008) Diagnosis and treatment of Wilson disease: an update. Hepatology 47:2089–2111
Schilsky ML (2017) Wilson disease: Diagnosis, Treatment, and Follow-up. Clin Liver Dis 21:755-767
Walshe JM (1956) Wilson’s disease; new oral therapy. Lancet 270:25–26
Walshe JM (2011) The pattern of urinary copper excretion and its response to treatment in patients with Wilson’s disease. QJM 104:775–778
Walshe JM (2012) Serum ‘free’ copper in Wilson disease. QJM 105:419–423
Acknowledgements
We are grateful to the patients participating in this trial. We thank Mrs. Jessica Langel for the documentary assistance.
Funding
This is a non-funded study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None of the authors has any competing interests to declare.
Additional information
Responsible Editor: Robin Lachmann
Rights and permissions
About this article
Cite this article
Pfeiffenberger, J., Lohse, C.M., Gotthardt, D. et al. Long-term evaluation of urinary copper excretion and non-caeruloplasmin associated copper in Wilson disease patients under medical treatment. J Inherit Metab Dis (2018). https://doi.org/10.1007/s10545-018-0218-8
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s10545-018-0218-8